A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Journal of Cerebral Blood Flow and Metabolism

• Publication date

  1990-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/jcbfm.1990.59PMID 2329119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis of racemic (+) and (-) N-[methyl-11C]nomifensine, a ligand for evaluation of monoamine re-uptake sites by use of positron emission tomography.

  1989cited by this paper
• Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease

  1988cited by this paper
• [3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy.

  1988cited by this paper
• Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease

  1988cited by this paper
• Physical performance of the latest generation of commercial positron scanner

  1988cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers.

  1988cited by this paper
• In vivo evaluation of striatal dopamine reuptake sites using 11C‐nomifensine and positron emission tomography

  1987cited by this paper
• Metabolism of nomifensine after oral and intravenous administration

  1986cited by this paper
• Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes.

  1985cited by this paper
• Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations

  1985cited by this paper
• Quantitative autoradiography of 3H-nomifensine binding sites in rat brain.

  1985cited by this paper
• Stereoselective inhibition of synaptosomal catecholamine uptake by nomifensine.

  1984cited by this paper
• Kinetics and metabolism of nomifensine.

  1984cited by this paper
• A new headholder for PET, CT, and NMR imaging.

  1984cited by this paper
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

  1984cited by this paper
• Quantitation in Positron Emission Computed Tomography: 5. Physical–Anatomical Effects

  1981cited by this paper
• Quantitative Measurement of Regional Cerebral Blood Flow and Oxygen Metabolism in Man Using 15O and Positron Emission Tomography: Theory, Procedure, and Normal Values

  1980cited by this paper
• The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method.

  1974cited by this paper

• Sample preparation techniques for protein binding measurement in radiopharmaceutical approaches: A short review.

  2020cites this paper
• Positron emission tomography imaging in neurological disorders

  2012cites this paper
• Positron emission tomography neuroimaging in Parkinson's disease.

  2011cites this paper
• PET studies of the dopamine system in relation to cognitive functions

  2007cites this paper
• Positron Emission Tomography

  2006cites this paper
• PET and SPECT Imaging in Atypical Parkinsonian Disorders

  2005cites this paper
• Tracer Kinetic Modeling in PET

  2005cites this paper
• Positron emission tomography imaging of transplant function

  2004cites this paper
• Positron emission tomography imaging of transplant function

  2004cites this paper
• Functional brain imaging in the differential diagnosis of Parkinson's disease.

  2004cites this paper
• In Vitro and In Vivo Imaging of the Human Dopamine Transporter in Cocaine Abusers

  2002cites this paper
• [11C,127I] Altropane: A highly selective ligand for PET imaging of dopamine transporter sites

  2001cites this paper
• [123I]β‐CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients

  2001cites this paper
• AUTONOMIC DYSFUNCTION IN PARKINSON'S DISEASE AND ITS CORRELATES TO MEDICATION AND DOPAMINE TRANSPORTER BINDING

  2001cites this paper
• Combining Functional MRI with Neurochemical Mapping Obtained with PET and SPECT

  2000cites this paper
• Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease

  2000cites this paper
• 17 – Neurodegenerative Disorders of the Cerebellum

  2000cites this paper
• The effects of surgical treatment of Parkinson's disease on brain function: PET findings.

  2000cites this paper
• PET studies of brain monoamine transporters.

  2000cites this paper
• Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease.

  1999cites this paper
• NMDA‐Receptor Activity Visualized with (S)‐[N‐Methyl‐11C]Ketamine and Positron Emission Tomography in Patients with Medial Temporal Lobe Epilepsy

  1999cites this paper
• [Value of functional imaging in Parkinson's disease and related movement disorders].

  1999cites this paper
• Brain Serotonin and Dopamine Transporters in Depressive Children

  1999cites this paper
• Positron emission tomography studies in movement disorders.

  1998cites this paper
• The early diagnosis of parkinson's disease

  1998cites this paper
• Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography.

  1997cites this paper
• Advances in imaging Parkinson's disease.

  1997cites this paper
• Positron emission tomography studies of healthy volunteers-no effects on the dopamine terminals and synthesis after short term exposure to toluene

  1997cites this paper
• Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects

  1997cites this paper
• Positron emission tomography in parkinsonism.

  1997cites this paper
• Pet Imaging of Neurotransmission Systems in Neurology

  1997cites this paper
• The Dopamine Transporter in Human Brain

  1997cites this paper
• PET and SPECT studies in Parkinson's disease.

  1997cites this paper
• Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey.

  1997cites this paper
• Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.

  1997cites this paper
• Iodine-123 labeled derivatives of methylphenidate : Potential spect radiopharmaceuticals for brain dopamine transporters

  1996cites this paper
• A simple method for the quantification of benzodiazepine receptors using iodine-123 iomazenil and single-photon emission tomography

  1996cites this paper
• Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease

  1996cites this paper
• Cocaine congeners as PET imaging probes for dopamine terminals.

  1996cites this paper
• Cocaine Uptake Is Decreased in the Brain of Detoxified Cocaine Abusers

  1996cites this paper
• Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter

  1996cites this paper
• PET evaluation of the dopamine system of the human brain.

  1996cites this paper
• Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography.

  1996cites this paper
• Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter.

  1996cites this paper
• POSITRON EMISSION TOMOGRAPHY: Biomedical Research and Clinical Application

  1995cites this paper
• Central nervous system effects of subdissociative doses of (S)‐ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers

  1995cites this paper
• Imaging the head: functional imaging.

  1995cites this paper
• A new PET ligand for the dopamine transporter: studies in the human brain.

  1995cites this paper
• PET studies of the striatal dopaminergic system in Parkinson's disease (PD).

  1995cites this paper
• Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain.

  1995cites this paper
• PET imaging of neocortical monoaminergic terminals in Parkinson's disease

  1995cites this paper
• Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine.

  1995cites this paper
• Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers

  1995cites this paper
• Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain.

  1995cites this paper
• Radioactive Isotopes in Clinical Medicine and Research

  1995cites this paper
• Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET).

  1994cites this paper
• Pharmacokinetics and in vivo specificity of [LLC]dl‐threo‐methylphenidate for the presynaptic dopaminergic neuron

  1994cites this paper
• Synthesis of the racemate and individual enantiomers of [11C]methylphenidate for studying presynaptic dopaminergic neuron with positron emission tomography

  1994cites this paper
• Positron emission tomography and central neurotransmitter systems in movement disorders

  1994cites this paper
• In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography.

  1994cites this paper
• Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects.

  1994cites this paper
• SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates

  1993cites this paper
• Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide

  1993cites this paper
• Synthesis of halogenated analogs of 5-(4-chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]-isoindole or mazindol for exploration of the dopamine transporter

  1993cites this paper
• Positron-emitting radioligands for studies in vivo-probes for human psychopharmacology

  1993cites this paper
• Synthesis of [11C]tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies.

  1993cites this paper
• Functional imaging in relation to parkinsonian syndromes.

  1993cites this paper
• In vivo distribution of catecholamine reuptake sites in human brain gives clues to the physiopathology of MPTP-induced parkinsonism.

  1992cites this paper
• The distribution of radioactivity in brains of rats given [N-methyl-11C]PK 11195 in vivo after induction of a cortical ischaemic lesion.

  1992cites this paper
• Mapping of Histamine H1 Receptors in the Human Brain Using [11C]Pyrilamine and Positron Emission Tomography

  1992cites this paper
• Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism

  1992cites this paper
• Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography

  1992cites this paper
• Synthesis and in vitro binding properties of halogenated analogues of GBR as new dopamine uptake carrier ligands.

  1992cites this paper
• Efficacy of cyclophosphamide in sarcoid radiculomyelitis.

  1992cites this paper
• In vivo and in vitro studies of the dopaminergic system in movement disorders.

  1992cites this paper
• In vivo binding of [11C]tetrabenazine to vesicular monoamine transporters in mouse brain.

  1992cites this paper
• Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site.

  1992cites this paper
• Investigation of the Dopamine System with Positron Emission Tomography: General Issues in Modelling

  1991cites this paper
• Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies

  1991cites this paper
• Movement Disorders: the clinical issues

  1991cites this paper
• Dopamine Reuptake Sites: The Issues

  1991cites this paper
• The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

  1990cites this paper
• Positron emission tomography.

  1990cites this paper
• Positron emission tomography studies of neurotransmitter systems

  1990cites this paper
• Journal of Cerebral Blood Flow and Metabolism Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to E8p]cyclofoxy and Positron Emission Tomography Cyclofoxy Infusion for Opiate Receptor Quant/tat/on Theory Compartment Models for Receptor-binding Radiotracers

  year unknowncites this paper
• Positron emission tomography imaging in Parkinson ’ s disease

  year unknowncites this paper